1. Hastings R., Howell R., Betts D., et al. A common European framework for quality assessment for constitutional, acquired and molecular cytogenetic investigations. European cytogeneticists association newsletter. 2012. URL: https://www.e-c-a.eu/files/downloads/Guidelines/E.C.A._General_Guidelines_Version-2.0.pdf.
2. Lazareva O.V., Maloletkina E.S., Tuaeva A.A., et al. Technology for assessing the quality of medical care on the profile of “hematology” in the regions the Russian Federation during offsite events. Voprosy onkologii. 2022; 68(S3): 60–1. (In Russian).
3. Maloletkina E.S, Lazareva O.V., Parovichnikova E.N. Availability of the use of cytogenetic (CG) and molecular genetic studies (MG) at the expense of compulsory medical insurance (CHI) in the provision of specialized medical care (SMC) to patients with oncohematological disorders. Evrazijskij onkologicheskij zhurnal. 2022; 10(S2): 716–7. (In Russian).
4. The number of resident population of the Russian Federation by municipalities as of January 1, 2022, excluding the results of the All-Russian Population Census 2020 (2021). URL: https://rosstat.gov.ru/compendium/document/13282. (In Russian).
5. Davé B., Sanger W. Genomic microarray technologies for the cytogenetics laboratory. In: The AGT Cytogenetics Laboratory Manual. Eds M.S. Arsham, M.J. Barch, H.J. Lawce. 2017. DOI: 10.1002/9781119061199.ch18.